Insulin Sensitivity

Insulin Sensitivity

Insulin sensitivity describes how effectively the body’s tissues respond to insulin, the primary hormone responsible for facilitating glucose uptake from the blood into cells. When insulin sensitivity is high, relatively small amounts of insulin are sufficient to maintain normal blood glucose levels after meals and during fasting. Conversely, reduced insulin sensitivity—known as insulin resistance—requires progressively greater insulin output from pancreatic beta cells to achieve the same glycemic effect, eventually overwhelming the beta cells’ compensatory capacity and leading to type 2 diabetes.

Insulin sensitivity is influenced by multiple factors, including body composition (particularly visceral adipose tissue), physical activity, genetics, age, and hormonal status. Visceral fat is especially detrimental because it releases inflammatory cytokines and free fatty acids that directly impair insulin signaling in the liver and skeletal muscle. This relationship explains why weight loss is one of the most effective interventions for improving insulin sensitivity, with even a 5–7% reduction in body weight producing clinically meaningful improvements in insulin-mediated glucose disposal.

Retatrutide improves insulin sensitivity through both direct and indirect mechanisms. Weight loss reduces visceral adipose tissue and its associated inflammatory burden, restoring more normal insulin signaling. GLP-1 and GIP receptor activation directly enhance beta-cell insulin secretion in a glucose-dependent manner, reducing the metabolic demand on the insulin signaling pathway. Glucagon receptor agonism promotes hepatic lipid clearance, which reduces hepatic insulin resistance. In Phase 2 trials, these combined effects were reflected in substantial HbA1c reductions and improvements in fasting insulin and HOMA-IR indices across all dose groups.